476181-74-5

Basic information

• Product Name: CNTO 148
• Synonyms: CNTO 148;Golimumab;Simponi
• CAS NO: 476181-74-5
• Mol File: 476181-74-5.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: CNTO 148(CAS DataBase Reference)
• NIST Chemistry Reference: CNTO 148(476181-74-5)
• EPA Substance Registry System: CNTO 148(476181-74-5)

Safety Data

• Hazardous Substances Data: 476181-74-5(Hazardous Substances Data)

Usage

Description

CNTO 148 is a human anti-TNF-α monoclonal antibody that targets the proinflammatory cytokine tumor necrosis factor-alpha (TNF-α), which is implicated as the primary mediator of articular inflammation in diseases such as RA, PsA, and AS.
Used in Pharmaceutical Industry:
CNTO 148 is used as a biologic agent for the treatment of immunoinflammatory disorders by blocking TNF-α. It is currently approved for the treatment of RA in combination with methotrexate (MTX), PsA alone or in combination with MTX, and AS.
Used in Allergy Treatment:
CNTO 148 is used as a treatment for allergic asthma by targeting and neutralizing TNF-α, reducing inflammation and alleviating symptoms.

Originator

Centocor Ortho Biotech (US)

Side effects

The most common adverse reactions, occurring with an incidence >5%, were upper respiratory tract infection and nasopharyngitis. Regarding drug interactions, live vaccines should not be administered while being treated with golimumab. As an increased risk of serious infection has been associated with concomitant use of abatacept and anakinra, combination of these drugs is not recommended. Also, golimumab treatment should not be initiated in patients with an active infection. Furthermore, patients should be warned about the higher incidence of malignancies observed with anti-TNF-a therapy and increased risks of worsening or new onset of heart failure, of exacerbation or new onset of demyelinating disease, and of hepatitis B reactivation.